Biotech IV Monitor

IMVT — Immunovant Inc.

$8.1B market cap · 7 upcoming readouts tracked

Clinical trial readout dates for Immunovant Inc., compiled from ClinicalTrials.gov, alongside the SEC filings where results are announced. The next expected readout is May 2027.

Next readoutMay 2027in ~6 months
Upcoming readouts71 Phase 3
Market cap$8.1B
Cash & investments$722M~7 quarters at last loss rate
Recent 8-K filings1latest 2026-11-09

Upcoming readouts

Phase 2 IMVT-1402
Graves' Disease · NCT07018323
May 2027
Recruiting
Phase 2 IMVT-1402
Rheumatoid Arthritis · NCT06754462
September 2027
Ongoing
Phase 3 IMVT-1402
Generalized Myasthenia Gravis · NCT07039916
December 2027
Recruiting
Phase 2 IMVT-1402
Graves' Disease · NCT06727604
June 2028
Recruiting
Phase 2 IMVT-1402
Primary Sjögren's Syndrome · NCT06979531
July 2028
Ongoing
Phase 2 Imeroprubart
Chronic Inflammatory Demyelinating Polyneuropathy · NCT07032662
August 2028
Recruiting
Phase 2 IMVT-1402
Graves' Disease · NCT07286006
March 2030
Enrolling

Cash position

Immunovant Inc. reported $722M in cash, cash equivalents and marketable securities at Sep 30, 2026 (10-Q filed 2026-11-09). Its net loss for that quarter was $97M; at that rate the cash would last about 7 quarters. This is a rough guide: net loss includes non-cash items such as stock compensation, and does not count money the company may raise, so its own runway guidance can differ.

Recent SEC filings

8-K Results of Operations — earnings, may carry pipeline updates2026-11-09

Companies working on similar indications

Discussion

No messages yet. If you follow IMVT, you can start the conversation.
Track IMVT in real time
See live implied volatility for IMVT and 106 other biotechs, and get alerted when a readout lands.
🔔 Alert me on IMVT
Contact — questions or corrections about IMVT: dukeupt@gmail.com